Navigation Links
Genoptix Reports Strong Growth for the First Quarter of 2009
Date:4/30/2009

reasing from 2.1% for the first quarter of 2008. In the first quarter of 2009, the Company operated as a fully taxed corporation, following the recognition of the remaining available deferred tax assets in the last half of 2008.

Net income was $5.9 million for the first quarter of 2009, compared to net income of $5.0 million for the first quarter of 2008. Diluted earnings per share, or EPS, for the first quarter of 2009 was $0.33 based on 17.8 million weighted average common shares outstanding. This compares to EPS of $0.29 for the first quarter of 2008, which would have been reduced by approximately $0.13 if taxed at the current rate.

As of March 31, 2009, the Company's total cash, cash equivalents and investment securities were $111.5 million. For the first quarter of 2009, cash generated from operations was $5.3 million, while purchases of capital equipment for the same period totaled $1.6 million. The first quarter of 2009 ended with bad debt expense at approximately 3% of total revenues and days sales outstanding of 67 days, down from 71 days in the first quarter of 2008.

"We have continued to develop and strengthen the organization in the first quarter, moving forward with our growth initiatives and our hiring plan. In the first quarter, our sales team grew to 62 field representatives, up from 55 at the end of 2008 and moving us closer to our goal of 85 representatives by the end of 2009," said Sam Riccitelli, Genoptix EVP and COO. "We also increased the size of the Cartesian Medical Group, bringing the total number of hematopathologists to 26 and keeping us on track toward our goal of housing approximately 37 physicians by year-end."

Revised 2009 Performance Outlook

For the full-year 2009, Genoptix expects revenues of between $170 to $175 million, up from previous expectations of approximately $170 million, with gross margins in the high-fiftieth percentile.

<
'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Genoptix, Inc. Announces Pricing for Initial Public Offering
2. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
3. Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
4. Genoptix Announces Filing of Registration Statement for Secondary Public Offering of Common Stock
5. Genoptix Announces Pricing of Secondary Public Offering
6. Genoptix Announces Participation at Cowen and Company 28th Annual Health Care Conference
7. Genoptix Announces Participation at Lehman Brothers 11th Annual Global Health Care Conference
8. Genoptix Announces 2008 Annual Stockholders Meeting and Date of Record
9. Genoptix Announces Participation at the Bank of America 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for First Quarter 2008
11. Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne wedding ... revenues in the past three years. Today, the business announces ... According to the sales manager of the company, this is ... 2015. This point can be reflected on the discounted wedding ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... January 22, 2015 JJsHouse.com is a famous ... Today, the business announces its latest collection of wedding ... “The most important issue is the wedding dress on your ... in a woman’s life. Every bride wants to find the ...
Breaking Medicine News(10 mins):Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... have discovered a key molecule needed to kill the blood ... institute,s Molecular Genetics of Cancer and Cancer and Haematology divisions ... to work the death- inducing molecule Bim is required. The ... on a two- or three-pronged attack on both the tumour ...
... researchers participated in more than 50 studies on improvements ... be presented at the 2011 Annual Meeting of the ... from June 3 through 7. Research highlights include: ... tumor response, adverse events and surgical complications in patients ...
... By Amanda Gardner HealthDay Reporter , SATURDAY, June ... common cancer drug, Avastin, may benefit both early stage ovarian ... In both studies, presented Saturday at the annual meeting of ... was added to standard chemotherapy. But the high ...
... the University of North Carolina at Chapel Hill School ... transplantation of adult stem cells enriched with a bone-regenerating ... not healing properly. The UNC study team led ... biomedical engineering, demonstrated that stem cells manufactured with the ...
... people with knee injuries could benefit from a new type ... The world,s first clinical trial for the treatment of patients ... regulatory agency, the MHRA1, to commence. The current ... the meniscus, a procedure that often results in the early ...
... indicates that longer time to beginning adjuvant chemotherapy after surgery ... a study in the June 8 issue of JAMA ... published early online to coincide with its presentation at the ... cancer (CRC) is the third leading cause of cancer mortality ...
Cached Medicine News:Health News:New strategy to attack tumor-feeding blood vessels 2Health News:City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO 2Health News:City of Hope researchers to present rectal cancer, palliative care, benchmarking studies at ASCO 3Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 3Health News:Stem cell treatment may offer option for broken bones that don't heal 2Health News:Pioneering stem cell bandage receives approval for clinical trial 2Health News:Following colorectal cancer surgery, longer delay before chemotherapy associated with worse survival 2
(Date:1/23/2015)... 23, 2015  Today the U.S. Food and Drug Administration ... prevention of serogroup B meningococcal disease in ... Trumenba®, which received FDA approval in October, represent a ... "I have heard over and over ...
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ... Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and ... Size, Share, Growth, Trends and Forecast 2014 - 2020" ... At present, the global market for urinary catheters is ...
(Date:1/23/2015)... Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... DCVax® personalized immune therapies for operable and inoperable solid tumor ... present at the 7 th Annual Phacilitate Immunotherapy Forum ... Bio,s presentation at Phacilitate will take place on January 26 ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3
... Nov. 9, 2011 Reportlinker.com announces ... is available in its catalogue: ... in Europe - Reference Pricing and ... Drugs Pose Significant Challenge to Pharmaceutical ...
... Company (NYSE: KV.A/ KV.B) (the "Company" or "K-V"), today reported ... Food & Drug Administration ("FDA") approved product indicated to reduce ... who have a history of a singleton spontaneous preterm birth. ... 2011. From its launch date through October 31, 2011: ...
Cached Medicine Technology:Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 2Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 3Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 4Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 5Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 6Pharmaceutical Pricing and Reimbursement in Europe - Reference Pricing and Similar Initiatives Being Applied to Innovative Drugs Pose Significant Challenge to Pharmaceutical Companies 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 2K-V Pharmaceutical Announces Updated Makena® Performance Metrics 3K-V Pharmaceutical Announces Updated Makena® Performance Metrics 4K-V Pharmaceutical Announces Updated Makena® Performance Metrics 5K-V Pharmaceutical Announces Updated Makena® Performance Metrics 6K-V Pharmaceutical Announces Updated Makena® Performance Metrics 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 8
... the Antigen-Antibody Pens-Using a proprietary and patented ... fountain pens, called Antigen-Antibody pens-TM, that will ... blotting membranes in any form or shape ... dyes helps to see antigen being written ...
... Advantages of using the Antigen-Antibody Pens-Using ... designed and developed specialized fountain pens, called ... deliver or write/mark the blotting membranes in ... specially formulated antigen-bonded colored dyes helps to ...
... Liters of pure water, Complete, Compact Systems ... Water,Millipores compact S.D.S. Storage and Distribution Systems ... liters of purified water produced by Elix ... purity of stored water, provide effective protection ...
... 200 to 350 Liters of pure water, ... Distribution of Purified Water,Millipores compact S.D.S. Storage ... 200 to 350 liters of purified water ... to maintain consistent purity of stored water, ...
Medicine Products: